Flaharty Asset Management LLC Purchases 900 Shares of Gilead Sciences, Inc. $GILD

Flaharty Asset Management LLC raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3,600.0% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 925 shares of the biopharmaceutical company’s stock after purchasing an additional 900 shares during the quarter. Flaharty Asset Management LLC’s holdings in Gilead Sciences were worth $103,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. EPG Wealth Management LLC boosted its holdings in Gilead Sciences by 2.0% during the 2nd quarter. EPG Wealth Management LLC now owns 4,627 shares of the biopharmaceutical company’s stock valued at $513,000 after acquiring an additional 89 shares during the period. Southland Equity Partners LLC lifted its position in shares of Gilead Sciences by 2.9% during the second quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company’s stock worth $364,000 after purchasing an additional 92 shares during the last quarter. Putney Financial Group LLC lifted its position in shares of Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares during the last quarter. Twelve Points Wealth Management LLC boosted its stake in shares of Gilead Sciences by 1.5% during the second quarter. Twelve Points Wealth Management LLC now owns 6,499 shares of the biopharmaceutical company’s stock valued at $721,000 after purchasing an additional 98 shares during the period. Finally, Advantage Trust Co grew its holdings in shares of Gilead Sciences by 13.6% in the second quarter. Advantage Trust Co now owns 838 shares of the biopharmaceutical company’s stock worth $93,000 after purchasing an additional 100 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have issued reports on GILD. Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Needham & Company LLC lifted their price target on shares of Gilead Sciences from $133.00 to $140.00 and gave the company a “buy” rating in a research note on Thursday. Cantor Fitzgerald reissued an “overweight” rating and issued a $135.00 price objective on shares of Gilead Sciences in a research note on Friday, October 31st. Wolfe Research raised their price objective on Gilead Sciences from $135.00 to $140.00 and gave the stock an “outperform” rating in a report on Thursday, October 23rd. Finally, Royal Bank Of Canada upped their target price on Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a report on Friday, October 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $129.13.

Insider Buying and Selling

In other news, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $340,710.00. Following the sale, the insider directly owned 113,193 shares in the company, valued at approximately $12,855,329.01. This trade represents a 2.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $295,200.00. Following the transaction, the chief financial officer owned 157,055 shares of the company’s stock, valued at approximately $18,545,054.40. This trade represents a 1.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 94,646 shares of company stock worth $11,311,286 over the last ninety days. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $125.02 on Friday. The firm has a market cap of $155.11 billion, a price-to-earnings ratio of 24.90, a PEG ratio of 0.81 and a beta of 0.32. Gilead Sciences, Inc. has a 52-week low of $86.08 and a 52-week high of $127.68. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The company’s 50 day moving average is $117.44 and its 200 day moving average is $112.77.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. During the same quarter last year, the firm earned $2.02 EPS. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.99%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.